These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 25583358)

  • 21. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
    Cybulski C; Huzarski T; Byrski T; Gronwald J; Debniak T; Jakubowska A; Górski B; Wokołorczyk D; Masojć B; Narod SA; Lubiński J
    Clin Genet; 2009 Jan; 75(1):72-8. PubMed ID: 19021634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.
    Lener MR; Kashyap A; Kluźniak W; Cybulski C; Soluch A; Pietrzak S; Huzarski T; Gronwald J; Lubiński J
    Cancer Res Treat; 2017 Apr; 49(2):430-436. PubMed ID: 27488870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
    Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
    Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A; Dobricic J; Brankovic-Magic M
    J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
    Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
    Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Frequency of CHEK2 gene mutations in patients with breast cancer from the Republic of Bashkortostan].
    Mol Biol (Mosk); 2014; 48(1):55-61. PubMed ID: 25842825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer.
    Ansari N; Shahrabi S; Khosravi A; Shirzad R; Rezaeean H
    Lab Med; 2019 Jul; 50(3):e36-e41. PubMed ID: 31220302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Second Primary Thyroid Cancer in Women with Breast Cancer.
    Cieszyńska M; Kluźniak W; Wokołorczyk D; Cybulski C; Huzarski T; Gronwald J; Falco M; Dębniak T; Jakubowska A; Derkacz R; Marciniak W; Lener M; Woronko K; Mocarz D; Baszuk P; Bryśkiewicz M; Narod SA; Lubiński J
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
    Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
    Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.
    Huszno J; Budryk M; Kołosza Z; Tęcza K; Pamuła Piłat J; Nowara E; Grzybowska E
    Oncology; 2016; 90(4):193-8. PubMed ID: 26991782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
    Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF
    J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CHEK2-positive breast cancers in young Polish women.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubinski J
    Clin Cancer Res; 2006 Aug; 12(16):4832-5. PubMed ID: 16914568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing Cancer Risk Management between Females with Truncating
    Garmendia D; Weidner A; Venton L; Pal T
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
    Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J
    Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Germline
    Zhao Y; Yu T; Chen L; Xie D; Wang F; Fu L; Cheng C; Li Y; Zhu X; Miao G
    Thyroid; 2020 Jun; 30(6):924-930. PubMed ID: 32041497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma.
    Wójcicka A; Czetwertyńska M; Świerniak M; Długosińska J; Maciąg M; Czajka A; Dymecka K; Kubiak A; Kot A; Płoski R; de la Chapelle A; Jażdżewski K
    Genes Chromosomes Cancer; 2014 Jun; 53(6):516-23. PubMed ID: 24599715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of CHEK2 gene mutations in differentiated thyroid carcinoma patients using high resolution melting analysis.
    Fayaz S; Fard-Esfahani P; Torbati PM
    Asian Pac J Cancer Prev; 2014; 15(12):5019-22. PubMed ID: 24998580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
    Adank MA; Hes FJ; van Zelst-Stams WA; van den Tol MP; Seynaeve C; Oosterwijk JC
    Ned Tijdschr Geneeskd; 2015; 159():A8910. PubMed ID: 26332814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.